These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18416439)

  • 21. The pitfalls of field trials in fish vaccinology.
    Mitchell H
    Dev Biol Stand; 1997; 90():321-32. PubMed ID: 9270860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On design considerations and randomization-based inference for community intervention trials.
    Gail MH; Mark SD; Carroll RJ; Green SB; Pee D
    Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical guide to sample size calculations: non-inferiority and equivalence trials.
    Flight L; Julious SA
    Pharm Stat; 2016; 15(1):80-9. PubMed ID: 26604186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sample sizes in the multivariate analysis of repeated measurements.
    Vonesh EF; Schork MA
    Biometrics; 1986 Sep; 42(3):601-10. PubMed ID: 3567293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The consistency approach for the quality control of vaccines.
    Hendriksen C; Arciniega JL; Bruckner L; Chevalier M; Coppens E; Descamps J; Duchêne M; Dusek DM; Halder M; Kreeftenberg H; Maes A; Redhead K; Ravetkar SD; Spieser JM; Swam H
    Biologicals; 2008 Jan; 36(1):73-7. PubMed ID: 17892948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blinded sample size reassessment in non-inferiority and equivalence trials.
    Friede T; Kieser M
    Stat Med; 2003 Mar; 22(6):995-1007. PubMed ID: 12627414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical analysis of influenza vaccine lot consistency studies.
    Nauta J
    J Biopharm Stat; 2006; 16(4):443-52. PubMed ID: 16892906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size calculations for the development of biosimilar products.
    Kang SH; Kim Y
    J Biopharm Stat; 2014; 24(6):1215-24. PubMed ID: 25032735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Average bioequivalence evaluation: general methods for pilot trials.
    Pan G; Wang Y
    J Biopharm Stat; 2006; 16(2):207-25. PubMed ID: 16584068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statistical considerations for vaccine immunogenicity trials. Part 2: Noninferiority and other statistical approaches to vaccine evaluation.
    Plikaytis BD; Carlone GM
    Vaccine; 2005 Feb; 23(13):1606-14. PubMed ID: 15694513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE; Foulkes MA
    Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does placebo help establish equivalence in trials of new antidepressants?
    Barbui C; Violante A; Garattini S
    Eur Psychiatry; 2000 Jun; 15(4):268-73. PubMed ID: 10951612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An alternative to the use of two-sided tests in clinical trials.
    Dunnett CW; Gent M
    Stat Med; 1996 Aug; 15(16):1729-38. PubMed ID: 8870155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating sample size in clinical studies: basic methodological principles.
    Carneiro AV
    Rev Port Cardiol; 2003 Dec; 22(12):1513-21. PubMed ID: 15008067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Equivalence trials: methodologic analysis.
    Carneiro A
    Rev Port Cardiol; 2003 Sep; 22(9):1125-39. PubMed ID: 14655314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size and rejection limits for detecting reagent lot variability: analysis of the applicability of the Clinical and Laboratory Standards Institute (CLSI) EP26-A protocol to real-world clinical chemistry data.
    Kim S; Chang J; Kim SK; Park S; Huh J; Jeong TD
    Clin Chem Lab Med; 2020 Jul; 59(1):127-138. PubMed ID: 32628625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
    Dunnigan K; King DW
    Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of information and optimal clinical trial design.
    Willan AR; Pinto EM
    Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.